← Back to Search

GLP-1 Receptor Agonist

IDegLira for Type 2 Diabetes (REMITiDegLira Trial)

Phase 3
Waitlist Available
Led By Zubin Punthakee, MD
Research Sponsored by Population Health Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 weeks after randomization
Awards & highlights

Summary

This trial is testing if an intensive treatment with specific medications and lifestyle changes can help people with newly diagnosed type 2 diabetes manage their condition over time. The study involves 160 patients who will receive either this intensive treatment or regular diabetes care. The goal is to see if the intensive approach can lead to sustained diabetes remission without ongoing medication.

Eligible Conditions
  • Type 2 Diabetes

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 weeks after randomization
This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 weeks after randomization for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Proportion of participants achieving drug-free diabetes remission
Secondary study objectives
Proportion of participants achieving drug-free diabetes regression
Proportion of participants achieving drug-free normoglycemia

Side effects data

From 2022 Phase 3 trial • 145 Patients • NCT03737240
16%
Emergency Room Visits
8%
Diarrhea
8%
Abdominal Pain
5%
Hospital Readmissions
4%
Nausea
1%
Vomiting
100%
80%
60%
40%
20%
0%
Study treatment Arm
Basal-Bolus Insulin
IDegLira

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: InterventionExperimental Treatment4 Interventions
Drug: IDegLira - sc injection; Drug: metformin - oral administration; Drug: insulin degludec - sc injection; Behavioral: lifestyle therapy, diet and exercise
Group II: Standard CareActive Control1 Intervention
Standard glycemic care as informed by the current clinical practice guidelines
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
IDegLira
2021
Completed Phase 4
~1020
insulin degludec
2015
Completed Phase 3
~4690
Lifestyle Therapy
2021
Completed Phase 3
~460
Metformin
2006
Completed Phase 4
~2430

Find a Location

Who is running the clinical trial?

Novo Nordisk A/SIndustry Sponsor
1,546 Previous Clinical Trials
2,443,750 Total Patients Enrolled
Population Health Research InstituteLead Sponsor
162 Previous Clinical Trials
713,102 Total Patients Enrolled
Zubin Punthakee, MDPrincipal InvestigatorMcMaster University
~25 spots leftby Oct 2025